Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer

Clinical Pharmacokinetics

Volumn 43, Issue 8, 2004, Pages 529-538

  Robertson, John F R ^a   Erikstein, Bjorn ^b   Osborne, Kent C ^c   Pippen, John ^d   Come, Steven E ^e   Parker, Leroy M ^f   Gertler, Stan ^g   Harrison, Mike P ^h   Clarke, David A ^h  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b Radium Hospital   (Norway)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d TEXAS ONCOLOGY   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g OTTAWA REGIONAL CANCER CENTRE   (Canada)

^h ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; FULVESTRANT; LONG ACTING DRUG; PLACEBO;

ADULT; ADVANCED CANCER; AGED; ANALYTICAL PARAMETERS; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE DRUG DOSE; OPEN STUDY; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STEADY STATE; TANDEM MASS SPECTROMETRY; VARIANCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AREA UNDER CURVE; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HALF-LIFE; HUMANS; METABOLIC CLEARANCE RATE; MIDDLE AGED; POSTMENOPAUSE;

EID: 3042847696     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200443080-00003     Document Type: Article

References (14)

1. Dixon JM, Nicholson RI, Robertson JFR, et al. Comparison of the short-term biological effects of fulvestrant (ICI 182,780) with tamoxifen in postmenopausal women with primary breast cancer [abstract no. 161]. Eur J Cancer 2000; 36 Suppl. 5: S73
2. Howell A, Osborne CK, Morris C, et al. ICI 182,780 (Fas-lodex™): development of a novel 'pure' antiestrogen. Cancer 2000; 89: 817-25
3. Curran M, Wiseman L. Fulvestrant. Drugs 2001; 61: 807-13
4. Jordan VC, Murphy CS. Endocrine pharmacology of antiestrogens as antitumour agents. Endocr Rev 1990; 11: 578-610
5. MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 1998; 50: 151-96
6. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991; 51: 3867-73
7. Howell A, DeFriend DJ, Robertson JF, et al. Pharmacokinetics, pharmacological and anti-tumour effects of the specific antioestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 1996; 74: 300-8
8. Howell A, Robertson JFR, Quaresma Albano J, et al. Fulvestrant (formerly ICI 182,780) is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20: 3396-403
9. Osborne CK, Pippen J, Jones SE, et al. A double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in post-menopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002; 20: 3386-95
10. Robertson J, Nicholson R, Gee J, et al. The pharmacokinetics of single-dose Faslodex™ (ICI 182,780) in post-menopausal primary breast cancer: relationship with estrogen receptor (ER) down-regulation [abstract no. 362]. Proc Am Soc Clin Oncol 2000; 19: 94A
11. A phase I trial to assess the safety, tolerability, and pharmacokinetics of single ascending intravenous doses of ICI 182,780 (ZC9238) in healthy males volunteers, 9238IL/0026. Maccles-field: AstraZeneca, 1997. (Data on file)
12. Shargel L, Yu ABC. Applied biopharmaceutics and pharmacokinetics. 3rd ed. Norwalk (CT): Appleton & Lange, 1993
13. Boxenbaum H. Pharmacokinetic tricks and traps: flip-flop models. J Pharm Sci 1998; 1: 90-1
14. Robertson JFR. A comparison of the single-dose pharmacokinetics (PK) of Faslodex (ICI 182,780) 250mg when given as either a one x 5-mL intra-muscular (I.M) injection or two x 2.5-mL injections in postmenopausal (PM) women with advanced breast cancer (ABC) [abstract 172]. Breast Cancer Res Treat 2000; 64: 53